Prior corticosteroid treatment alters cPBMC composition and IFNγ response to immunotherapy in canine cancer
Overall, we observed trends suggesting that prior corticosteroid therapy may compromise the efficacy of PD-1/PD-L1 axis blockade and IL-12 in dogs with cancer. While the dose and timing of corticosteroid administration in this study reflected clinical reality and would not justify withholding this emerging therapeutic option, corticosteroid pretreatment may be a confounder for PD-1/PD-L1 axis blockade or IL-12 therapy in canine oncology.
Authors
- Sonja Hartnack (ORCID: https://orcid.org/0000-0002-5757-5708)
- Anna Barbara Emilia Zimmermann
- Betül Taşkoparan (ORCID: https://orcid.org/0000-0003-1890-1547)
- Stanislav Pantelyushin (ORCID: https://orcid.org/0000-0002-3490-3860)
- Daniel Fuchs (ORCID: https://orcid.org/0009-0007-1472-4391)
- Carla Rohrer Bley (ORCID: https://orcid.org/0000-0002-5733-2722)
- Manuela Schnyder (ORCID: https://orcid.org/0000-0002-6523-7952)
- Johannes vom Berg (ORCID: https://orcid.org/0000-0002-4086-1564)
- Mathischan Maheswaran
Institutions
- University of Zurich (CH)
- University Hospital of Zurich (CH)
- Center for Pediatric Endocrinology Zurich (CH)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1544949
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Universität Zürich